- Trial phase
- Approved
- Time to market
- Already on the market since 1998 (US) and 1999 (FDA licensure). No new regulatory filing is pending.
- Why 3/10
- Thymoglobulin is already approved and commercialized with no pending PDUFA, pivotal readout, or other hard binary catalyst in the next 12 months. It represents less than 1% of Sanofi's total revenue, so even a major sales swing would have negligible impact on SNY's share price.
Thymoglobulin has no near-term binary catalysts. Watch for Sanofi's full-year 2026 results (expected late January 2027) for the annual sales figure, and monitor for any biosimilar development that could pressure the franchise. Neither event is likely to materially move SNY shares given the drug's tiny revenue contribution.
Price Chart
Executive Summary
Thymoglobulin (anti-thymocyte globulin [rabbit]) is Sanofi's mature, FDA-approved biologic for preventing and treating acute rejection in kidney transplant patients. First approved in 1998, it generates steady but modest revenue (EUR 134 million in Q3 2026, up 10.2% YoY). The drug received supplemental FDA label approvals in January and June 2026. For a non-medical investor, Thymoglobulin is a slow-growing, low-volatility legacy product that is far too small within Sanofi's EUR 50+ billion annual revenue to move the stock. No upcoming binary catalysts exist.
How It Works
Thymoglobulin is a purified mixture of antibodies harvested from rabbits that have been immunized with human thymus cells. These antibodies bind to and destroy human T-cells (a type of white blood cell that drives organ rejection), suppressing the immune system to prevent or treat kidney transplant rejection.
Trial Status
Thymoglobulin was initially approved by the FDA in 1998 (first licensed May 19, 1999) for treatment of acute kidney transplant rejection, with a later approval in 2017 for prophylaxis (prevention) of acute rejection. It is a mature, commercially marketed biologic. The FDA approved supplemental labeling updates in January 2026 and June 2026.
The Two-Sided Case
Upcoming Catalysts
- No hard binary catalysts are scheduled. The product is mature and already approved; future catalysts would be limited to routine label updates, biosimilar entry, or manufacturing expansions.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sanofi 6-K SNY ·Originating report